
Selskapsdetaljer
MaaT Pharma is a late-stage biotechnology company and a leader in the development of intestinal microbiota-based drugs designed to modulate the immune system of cancer patients and improve their survival.
A pioneer in its field, MaaT Pharma is developing the first immunomodulatory drug candidate based on intestinal microbiota in oncology, currently in phase 3 clinical evaluation. Thanks to its proprietary pooling (combining donations of healthy microbiota) and microbial co-culture technologies, MaaT Pharma is developing standardised drugs with high bacterial diversity, aimed at improving the survival of cancer patients.
Kilde:
Cofisem
-
Sist oppdatert:
11 Feb 2025
Ledelse
Chief Executive Officer | Hervé Affagard | ||||
Chief Financial Officer | Eric Soyer | ||||
Chief Commercial Officer | Jonathan Chriqui | ||||
Chief Technology Officer | Carole Schwintner | ||||
Kilde: Cofisem - Sist oppdatert: 11 Feb 2025 |
Key figures
Millenium | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Net sales | 2.228 | 1.430 | 972 | ||
Income from ordinary activities | 2.228 | 1.430 | 972 | ||
Operating income | -19.943 | -13.557 | -8.893 | -5.252 | -4.965 |
Cost of financial indebtedness net | 402 | 185 | 121 | 45 | 20 |
Equity-accounted companies contribution to income | |||||
Net profit from discontinued activities | |||||
Net income | -19.717 | -13.713 | -9.019 | -5.301 | -5.844 |
Net income (Group share) | -19.717 | -13.713 | -9.019 | -5.301 | -5.844 |
Fiscal year end | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
Kilde: Cofisem - Sist oppdatert: 11 Feb 2025 |
Største aksjonærer
Adresse
MaaT Pharma
70 Avenue Tony Garnier
FR-69007
Lyon
France
Telefonnummer:
+33 (0)4 28 29 14 00
Kilde:
Cofisem
-
Sist oppdatert:
11 Feb 2025